Receptor News and Research

RSS

Study suggests that existing HIV drug could be a potential therapy for Staph infections

A new study by NYU School of Medicine researchers suggests that an existing HIV drug called maraviroc could be a potential therapy for Staphylococcus aureus, a notorious and deadly pathogen linked to hundreds of thousands of hospitalizations each year.

15 Dec 2012

ETA receptor antagonism reduces novel cardiovascular risk factors in patients with CKD

Blocking the receptor for proteins that constrict blood vessels reduces markers of heart-related problems in patients with chronic kidney disease (CKD), according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN).

14 Dec 2012

Administration of N2O + ISO appears to have negative effect on fetal development

An anesthetic regimen typically used during surgery on pregnant mothers appears to have a negative effect on the development of the fetus, according to a new study on mice conducted by neurobiologists from the National Center for Toxicological Research, in Arizona.

14 Dec 2012

SLU researchers to study physiological and biochemical functions in lupus

Two researchers at Saint Louis University's division of rheumatology in the department of internal medicine have been awarded a $1.8 million NIH grant to study the physiological and biochemical functions in lupus, an autoimmune disease, and develop possible new medications for its treatment.

14 Dec 2012

EZH2 protein enables advanced prostate cancers to spread without stimulation by male hormones

Scientists at Dana-Farber Cancer Institute have discovered a molecular switch that enables advanced prostate cancers to spread without stimulation by male hormones, which normally are needed to spur the cancer's growth. They say the finding could lead to a new treatment for prostate cancers that are no longer controlled by hormone-blocking drugs.

14 Dec 2012

Pfizer, Ligand announce FDA acceptance of bazedoxifene/conjugated estrogens NDA

Pfizer Inc. and Ligand Pharmaceuticals Incorporated today announced that the United States Food and Drug Administration (FDA) accepted for review a New Drug Application (NDA) for bazedoxifene/conjugated estrogens (BZA/CE), a potential new medicine for non-hysterectomized women for the treatment of moderate-to-severe vasomotor symptoms (VMS) and vulvar and vaginal atrophy (VVA) associated with menopause, as well as the prevention of postmenopausal osteoporosis.

14 Dec 2012

New way to effectively make designer drugs that hit collections of protein targets simultaneously

An international research collaboration led by scientists at the University of North Carolina School of Medicine and the University of Dundee, in the U.K., have developed a way to efficiently and effectively make designer drugs that hit multiple protein targets at once.

13 Dec 2012

Opioids already in the body can enhance malignant tendencies of human cancer cells

A study led by University of Chicago researcher Patrick A. Singleton, Ph.D. and published in the journal Anesthesiology has shown that, even without the addition of further opioids such as morphine, opioids already in the body can enhance the malignant tendencies of human cancer cells.

13 Dec 2012

TSEC strategy can benefit postmenopausal women

Investigators at Wake Forest Baptist Medical Center have concluded research on a new postmenopausal hormone therapy that shows promise as an effective treatment for menopausal symptoms and the prevention of osteoporosis without increasing the risk for heart disease or breast cancer.

13 Dec 2012

AZD6765 briefly improves treatment-resistant patients' depression symptoms in minutes

A drug that works through the same brain mechanism as the fast-acting antidepressant ketamine briefly improved treatment-resistant patients' depression symptoms in minutes, with minimal untoward side effects, in a clinical trial conducted by the National Institutes of Health. The experimental agent, called AZD6765, acts through the brain's glutamate chemical messenger system.

13 Dec 2012

Delayed childbearing may protect against triple-negative breast cancer

Younger women who wait at least 15 years after their first menstrual period to give birth to their first child may reduce their risk of an aggressive form of breast cancer by up to 60 percent, according to a Fred Hutchinson Cancer Research Center study.

12 Dec 2012

Review describes current state of lung cancer care

A review in the December issue of the journal Archives of Pathology & Laboratory Medicine by Paul Bunn Jr, MD, University of Colorado Cancer Center investigator and past president of ASCO, IASLC and AACI describes the current state of lung cancer care.

12 Dec 2012

Drugs that bind to specific serotonin receptors can improve and impair female sexual function

Drugs that bind to specific serotonin receptors in the brain can both improve and impair female sexual function in non-human primates.

12 Dec 2012

New coronavirus can infect cells from humans and bats alike

The SARS epidemic of 2002-2003 was short-lived, but a novel type of human coronavirus that is alarming public health authorities can infect cells from humans and bats alike, a fact that could make the animals a continuing source of infection, according to a study to be published in in mBio-, the online open-access journal of the American Society for Microbiology, on December 11.

11 Dec 2012

Combination of ibrutinib and rituximab shows promise against chronic lymphocytic leukemia

A two-prong approach combining ibrutinib and rituximab (Rituxin) to treat aggressive chronic lymphocytic leukemia (CLL) produced profound responses with minor side effects in a Phase 2 clinical trial at the University of Texas MD Anderson Cancer Center.

11 Dec 2012

Merrimack announces results from MM-302 Phase I trial on advanced HER2 positive breast cancer

Merrimack Pharmaceuticals, Inc. today announced Phase I clinical trial results for MM-302, the company's novel agent for the treatment of advanced HER2 positive (HER2+ or ErbB2+) breast cancer.

11 Dec 2012

Alpha arrestins may play a role in cell signaling that is crucial to new drug development

A newly found understanding of receptor signaling may have revealed a better way to design drugs. A study from Nationwide Children's Hospital suggests that a newly identified group of proteins, alpha arrestins, may play a role in cell signaling that is crucial to new drug development.

11 Dec 2012

Receptor News and Research

Study suggests that existing HIV drug could be a potential therapy for Staph infections

ETA receptor antagonism reduces novel cardiovascular risk factors in patients with CKD

Administration of N2O + ISO appears to have negative effect on fetal development

SLU researchers to study physiological and biochemical functions in lupus

EZH2 protein enables advanced prostate cancers to spread without stimulation by male hormones

Pfizer, Ligand announce FDA acceptance of bazedoxifene/conjugated estrogens NDA

New way to effectively make designer drugs that hit collections of protein targets simultaneously

Opioids already in the body can enhance malignant tendencies of human cancer cells

TSEC strategy can benefit postmenopausal women

AZD6765 briefly improves treatment-resistant patients' depression symptoms in minutes

Delayed childbearing may protect against triple-negative breast cancer

Review describes current state of lung cancer care

Drugs that bind to specific serotonin receptors can improve and impair female sexual function

New coronavirus can infect cells from humans and bats alike

Combination of ibrutinib and rituximab shows promise against chronic lymphocytic leukemia

Merrimack announces results from MM-302 Phase I trial on advanced HER2 positive breast cancer

Alpha arrestins may play a role in cell signaling that is crucial to new drug development

ATLAS holds up 10-year tamoxifen regime

RET fusion signals unique NSCLC subtype

FGFR1 amplification heralds poor prognosis in SCCL

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News